← Product Code [NAD](/submissions/SU/subpart-e%E2%80%94surgical-devices/NAD) · K043063 # OXYBAND WOUND DRESSING (K043063) _Oxyband Technologies, Inc. · NAD · Mar 24, 2005 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/NAD/K043063 ## Device Facts - **Applicant:** Oxyband Technologies, Inc. - **Product Code:** [NAD](/submissions/SU/subpart-e%E2%80%94surgical-devices/NAD.md) - **Decision Date:** Mar 24, 2005 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4020 - **Device Class:** Class 1 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use The Prescription OxyBand ™ Wound Dressings are intended to provide a moist environment to facilitate the normal wound healing process. OxyBand ™ Wound Dressings can be used to cover and protect wounds and catheter sites, or used as a secondary dressing for other wound products such as gauze, alginates, hydrogels, debridement facilitators, or a protective cover at risk skin. The OxyBand ™ Wound Dressings are indicated for: clean closed surgical incisions, skin graft donor sites, Stage I or II pressure sores, superficial wounds such as abrasions, skin tears, and blisters, lacerations, first and second degree burns, chafed skin, skin continuously exposed to moisture, secondary dressing over gauze, alginates or hydrogels. The Over-The-Counter OxyBand ™ Wound Dressings are intended to protect light to moderate wounds, including skin tears, scrapes, minor pressure sores, blisters, lacerations, minor burns, to protect chafed or irritated skin or skin continuously exposed to moisture, and to create a moist environment for wound healing. ## Device Story OxyBand is a multilayer wound dressing; provides moist environment; supplies oxygen to wound site. Applied directly over clean skin or wounds; remains in place up to 5 days. Dressing maintains elevated oxygen levels over wound area while intact. Used in clinical or home settings; applied by clinicians or patients. Protects against water, dirt, germs. Benefits include facilitated healing process and protection of compromised skin. ## Clinical Evidence Bench testing only. Study demonstrated that oxygen levels rise steadily over the device area for the first few hours after application and maintain elevated levels through 5 days while the dressing remains intact. ## Technological Characteristics Multilayer occlusive wound dressing. Designed to be water, dirt, and germ resistant. Provides oxygen supply to wound site. Form factor is a flexible adhesive dressing. No software or electronic components. ## Regulatory Identification An occlusive wound dressing is a nonresorbable, sterile or non-sterile device intended to cover a wound, to provide or support a moist wound environment, and to allow the exchange of gases such as oxygen and water vapor through the device. It consists of a piece of synthetic polymeric material, such as polyurethane, with or without an adhesive backing. This classification does not include an occlusive wound dressing that contains added drugs such as antimicrobial agents, added biologics such as growth factors, or is composed of materials derived from animal sources. ## Predicate Devices - 3M Medical Products Tegaderm ™ Transparent Dressing ([K973036](/device/K973036.md)) - Innovative Troudots Togaderin Film and Intelligent Film Dressings ([K973312](/device/K973312.md)) - Kinetic Concepts, Inc. KCI Wound Cell Transparent Wound Dressing ([K020781](/device/K020781.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ 043063 lot 4 #### 510(k) Summary of Safety and Effectiveness for the OxyBand III. Technologies OxyBand TM Wound Dressing This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with This STO(K) Bammary of the SMDA 1990 and 21 CFR 807.92. ### 1. General Information ### MAR 2 4 2005 OxyBand Technologies Submitter: 33 Bayview Terrace Mill Valley, CA 94941 Maureen O'Connell Contact Person: 5 Timber Lane North Reading, MA 01864 Telephone: 978-207-1245 Fax: 978-207-1246 March 16, 2005 Summary Preparation Date: 2. Names OxyBand TM Wound Dressing Device Name: Dressing, wound and burn, occlusive Classification Name: Product Code: MGP Panel: Plastic and Reconstructive Surgery Devices ### 3. Predicate Devices The OxyBand TM Wound Dressing is substantially equivalent to the 3M Medical Products Tegaderm ™ Transparent Dressing (K973036), the Innovative Troudots Togaderin Film and Intelligent Film and Intelligent Film Dressings (K973312) and the Kinetic Concepts, Inc. KCI Wound Cell Transparent Wound Dressing (K020781). ### 4. Device Description OxyBand™ is a multilayer wound dressing that keeps out water, dirt and germs, and supplies oxygen to the wound. It is designed to be applied directly over clean skin or wounds for up to 5 days. A study has shown that upon attaching the dressing over a test plate, oxygen levels rise steadily over the device area for the first few hours and then maintain at elevated levels through 5 days as long as the dressing remains intact and secure around the perimeter. {1}------------------------------------------------ K043063 2 of 4 ### 5. Indications for Use Indications for USE OxyBand ™ Wound Dressings are available as both Prescription and Over-The-Counter products. The Prescription OxyBand ™ Wound Dressings are intended to provide a moist The Prescription OxyBand --- Wound Dressings process. OxyBand T" Wound environment to facilitate the normal wounds and catheter sites, or used as a Diessings can be used to over and products such as gauze, alginates, hydrogels, secondary dressing for other would products sam as gisk skin. The OxyBaft TM debridement facilitators, or a protective cover at risk skin. The OxyBaff Wound Dressings are indicated for: clean closed surgical incisions, skin graft Wound Dressings are indicated ron orders, pressure sores, superficial wounds such donor sites, Stage For it pressure re, p. as abrasions, skin tears, and blisters, lacerations, first and second degree burns, as abrastons, skin tearing and to moisture, secondary dressing over gauze, alginates or hydrogels. The Over-The-Counter OxyBand ™ Wound Dressings are intended to protect File Over-The Counter OnyBana light to moderate wounds, including skin tears, scrapes, minor pressure sores, ifgit to moderate wounds, merading shirts, to protect chafed or irritated skin or abrasions, birsters, faceratems, and to create a moist environment for wound healing. {2}------------------------------------------------ # KOY 3063 # Indications for Use 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ K043063 Device Name:__________________________________________________________________________________________________________________________________________________________________ Indications For Use: OxyBand ™ Wound Dressings are intended to provide a moist environment to OxyBand '" Wound Dressings are intention to provide a more of the sunselves can facilitate the normal wound healing process. OxyBand The secondary facilitate the normal wound nearing process. Or used as a secondary be used to cover and protect wounds and catheres sites, budrogels be used to cover and protect wounds and as gauze, alginates, hydrogels, dressing for other would products such as sauze, arguitator, in a logo Co. debridement facilitators, or a protective cover at risk skin. The OxyBand TM assurent facilitators debridement facilitators, or a proceen to see surgical incisions, skin graft Wound Dressings are indicated for: clean closed surprisions, superficial wounds su Wound Dressings are indicated for. Crean oressure sores, superficial wounds such donor sites, Stage For If pressure areers, proens, first and second degree burns, as abrasions, skin tears, and blisters, lacerations, assessdage dressing over as abrasions, skin tears, and bilsters, nascraneses, in chafed skin, skin continuously exposed to moisture, secondary dressing over gauze, alginates or hydrogels. AND/OR Prescription Use _____________________________________________________________________________________________________________________________________________________________ メ (Part 21 CFR 801 Subpart D) Over-The-Counter Use _ (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Signature MATZALAN Land No. 12611 N(K) Nu... K04 3063 {3}------------------------------------------------ K043063 4 of 4 # Indications for Use K043063_______________________________________________________________________________________________________________________________________________________________________ 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ OxyBand™ Wound Dressings Device Name:__________________________________________________________________________________________________________________________________________________________________ Indications For Use: OxyBand ™ Wound Dressings are intended to protect light to moderations, OxyBand "" Wound Dressings are intence to pressure sores, blisters, lacerations, including skin tears, scrapes, minor pressure soressions, blisters, lacerations, including skin tears, scrapes, inthor prossure sores, as a more online ously exposed to minor burns, to protect chafed or irritated skin or skin continuously exposed to r mi millor burns, to protect enarous or wironment for wound healing. Prescription Use __ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ X (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .043063 {4}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/4/Picture/1 description: The image shows a logo with the words 'SERVICES USA' in a circular arrangement at the top left. Below the text is a symbol consisting of three stylized human profiles facing right. To the right of the symbol is a large, bold letter 'D', which is the only visible part of a word or phrase. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 MAR 2 4 2005 Oxyband Technologies, Inc. c/o Ms. Maureen O'Connell 5 Timber Lane North Reading, Massachusetts 01864 Re: K043063 Trade/Device Name: OxyBand™ Wound Dressings Regulatory Class: Unclassified Product Code: FRO Dated: March 10, 2005 Received: March 10, 2005 Dear Ms. O'Connell: We have reviewed your Section 510(k) premarket notification of intent to market the indication We have reviewed your Section 510(x) premained in substantially equivalent (for the indications referenced above and have determined the device is substance in interestate referenced above and nave determined the actived predicate devices marketed in interstate for use stated in the encrosule) to regary manced provice Medical Device Amendments, or to commerce prior to May 28, 1776, the enactions with the provisions of the Federal Food. Drug. devices that have been recuired in accordance was a premarket approval application (PMA). and Cosmetic Act (Act) that do not require approval of a premarket approval applicat and Cosment Act (Act) that do not require approval controls provisions of the Act. The You may, therefore, market the devices, baojest to annual registration, listing of general controls provisions of the rict mercial sequences against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it ( If your device is classified (sec above) into exist on major regulations affecting your device can may be subject to such additional controls. Existing major regulation EDA may be subject to such additional controlis. Entrologically in the 898. In addition, FDA may be found in the Code of Peacharies. publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please be advised that FDA s issuates of a bassaint... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . that FIFA has made a decemmation administered by other Federal agencies. You must or any Federal statutes and regulations administered of the registration and listing (21 Comply with an the Act 31equirements, meteans. In and actual and and and as a set CFR Part 807), fallemig (21 CFR Part 820); good if applicable, the electronic form in the quality systems (QU) regulation (Sections 531-542 of the Act); 21 CFR 1000-1050. product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1 {5}------------------------------------------------ Page 2 - Ms. Maureen O'Connell This letter will allow you to begin marketing your device as described in your Section 510(k) I his letter will anow you to ocgin mancemly your antial equivalence of your device to a legally premarket notification. The FDA inding of substantial before and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please s and the may of 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 If you desire specific advice for your de not of the Also, please not the regulation entitled, white in contact the Office of Comphanee at (210) 276 - 17 - 17 807.97). You may obtain "Misbranding by reference to prematics nothead.org the Act from the Division of Small other general information on your responsionnes and its toll-free number (800) 638-2041 or Manufacturers, International and Consumer Assistance to too corph/industry/support/index.html. Sincerely yours, for Miriam C. Provost, Ph.D. Acting Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ # KOY 3063 # Indications for Use K043063 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ Device Name:__________________________________________________________________________________________________________________________________________________________________ Indications For Use: OxyBand ™ Wound Dressings are intended to provide a moist environment to OxyBand - Wound Dressings are intended to process. OxyBand TM Wound Dressings can facilitate the normal wound healing process. OxyBand TM Wound Dressings can facilitate the normal wound noaling personal catheter sites, or used as a secondary be used to cover and process much as gauze, alginates, hydrogels, dressing for other would products such as sames as angeriasks skin. The OxyBand TM debridement facilitators, or a protective cover at risks skin. The OxyBand TM debrident facilitators, or a provice clean closed surgical incisions, skin graft Wound Dressings are marcated ronleers, pressure sores, superficial wounds such donor sites, Stage For II prossars rs, lacerations, first and second degree burns, as abrasions, skin tears, and onsters, nations, and to moisture, secondary dressing over gauze, alginates or hydrogels. AND/OR Prescription Use __ X (Part 21 CFR 801 Subpart D) Over-The-Counter Use _ (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Signature RESERVE BANK OF NEW ZEALAND 04 3063 {7}------------------------------------------------ ### 4 of 4 K043063 # Indications for Use 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ Device Name:__________________________________________________________________________________________________________________________________________________________________ Indications For Use: OxyBand ™ Wound Dressings are intended to protect light to moderate wounds, OxyBalld -- Would Dressings are messure sores, abrasions, blisters, lacerations, including skiff icals, scrapes, innits pressure sees), in continuously exposed to moisture, and to create a moist environment for wound healing. 1 AND/OR Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D) R Over-T Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) . ... .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ICO 43063 --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/NAD/K043063](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/NAD/K043063) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com